GlycoMimetics Inc (GLYC) - Total Assets
Based on the latest financial reports, GlycoMimetics Inc (GLYC) holds total assets worth $5.99 Billion USD as of March 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore GLYC operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
GlycoMimetics Inc - Total Assets Trend (2011–2024)
This chart illustrates how GlycoMimetics Inc's total assets have evolved over time, based on quarterly financial data. See GlycoMimetics Inc (GLYC) net assets for net asset value and shareholders' equity analysis.
GlycoMimetics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
GlycoMimetics Inc's total assets of $5.99 Billion consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 96.7% |
| Accounts Receivable | $136.58K | 1.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how GlycoMimetics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see GLYC market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: GlycoMimetics Inc's current assets represent 100.0% of total assets in 2024, an increase from 98.1% in 2011.
- Cash Position: Cash and equivalents constituted 96.7% of total assets in 2024, down from 97.5% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 1.2% of total assets.
GlycoMimetics Inc Competitors by Total Assets
Key competitors of GlycoMimetics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
GlycoMimetics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.29 | 6.28 | 15.81 |
| Quick Ratio | 2.29 | 6.28 | 15.81 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $3.38 Billion | $27.97 Million | $143.66 Million |
GlycoMimetics Inc - Advanced Valuation Insights
This section examines the relationship between GlycoMimetics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 300.17 |
| Latest Market Cap to Assets Ratio | 0.91 |
| Asset Growth Rate (YoY) | -75.5% |
| Total Assets | $11.09 Million |
| Market Capitalization | $10.13 Million USD |
Valuation Analysis
Near Book Valuation: The market values GlycoMimetics Inc's assets close to their book value (0.91x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: GlycoMimetics Inc's assets decreased by 75.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for GlycoMimetics Inc (2011–2024)
The table below shows the annual total assets of GlycoMimetics Inc from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $11.09 Million | -75.52% |
| 2023-12-31 | $45.32 Million | -12.54% |
| 2022-12-31 | $51.81 Million | -45.08% |
| 2021-12-31 | $94.35 Million | -33.95% |
| 2020-12-31 | $142.83 Million | -14.97% |
| 2019-12-31 | $167.97 Million | -21.82% |
| 2018-12-31 | $214.84 Million | +67.08% |
| 2017-12-31 | $128.58 Million | +203.35% |
| 2016-12-31 | $42.39 Million | -12.53% |
| 2015-12-31 | $48.46 Million | -15.37% |
| 2014-12-31 | $57.26 Million | +983.83% |
| 2013-12-31 | $5.28 Million | -71.32% |
| 2012-12-31 | $18.42 Million | -36.28% |
| 2011-12-31 | $28.91 Million | -- |
About GlycoMimetics Inc
GlycoMimetics, Inc. engages in the discovery and development of therapies for cancers and inflammatory diseases in the United States. The company was founded in 2003 and is based in Monrovia, Maryland.